Literature DB >> 10331951

Bestrophin gene mutations in patients with Best vitelliform macular dystrophy.

G M Caldwell1, L E Kakuk, I B Griesinger, S A Simpson, N J Nowak, K W Small, I H Maumenee, P J Rosenfeld, P A Sieving, T B Shows, R Ayyagari.   

Abstract

Best vitelliform macular dystrophy (VMD2) is an autosomal dominant dystrophy with a juvenile age of onset. Mutations in the Bestrophin gene were shown in patients affected with VMD2. In a mutation study, we made three new and interesting observations. First, we identified possible mutation hotspots within the gene, suggesting that particular regions of the protein have greater functional significance than others. Second, we described a 2-bp deletion in a part of the gene where mutations have not previously been reported; this mutation causes a frameshift and subsequent premature termination of the protein. Finally, we have evidence that some mutations are associated with variable expression of the disease, suggesting the involvement of other factors or genes in the disease phenotype. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10331951     DOI: 10.1006/geno.1999.5808

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  38 in total

Review 1.  [Morbus Best].

Authors:  O Strauss
Journal:  Ophthalmologe       Date:  2005-02       Impact factor: 1.059

Review 2.  Bestrophin 1 and retinal disease.

Authors:  Adiv A Johnson; Karina E Guziewicz; C Justin Lee; Ravi C Kalathur; Jose S Pulido; Lihua Y Marmorstein; Alan D Marmorstein
Journal:  Prog Retin Eye Res       Date:  2017-01-30       Impact factor: 21.198

3.  A missense mutation in ASRGL1 is involved in causing autosomal recessive retinal degeneration.

Authors:  Pooja Biswas; Venkata Ramana Murthy Chavali; Giulia Agnello; Everett Stone; Christina Chakarova; Jacque L Duncan; Chitra Kannabiran; Melissa Homsher; Shomi S Bhattacharya; Muhammad Asif Naeem; Adva Kimchi; Dror Sharon; Takeshi Iwata; Shaikh Riazuddin; G Bhanuprakash Reddy; J Fielding Hejtmancik; George Georgiou; S Amer Riazuddin; Radha Ayyagari
Journal:  Hum Mol Genet       Date:  2016-04-22       Impact factor: 6.150

4.  A novel compound heterozygous mutation in the BEST1 gene causes autosomal recessive Best vitelliform macular dystrophy.

Authors:  L Zhao; S Grob; R Corey; M Krupa; J Luo; H Du; C Lee; G Hughes; J Lee; J Quach; J Zhu; P X Shaw; I Kozak; K Zhang
Journal:  Eye (Lond)       Date:  2012-03-16       Impact factor: 3.775

Review 5.  Molecular genetics of macular degeneration.

Authors:  M A Musarella
Journal:  Doc Ophthalmol       Date:  2001-05       Impact factor: 2.379

Review 6.  Genotype-phenotype correlations and differential diagnosis in autosomal dominant macular disease.

Authors:  A Iannaccone
Journal:  Doc Ophthalmol       Date:  2001-05       Impact factor: 2.379

7.  BESTROPHIN1 mutations cause defective chloride conductance in patient stem cell-derived RPE.

Authors:  Yasmin Moshfegh; Gabriel Velez; Yao Li; Alexander G Bassuk; Vinit B Mahajan; Stephen H Tsang
Journal:  Hum Mol Genet       Date:  2016-05-18       Impact factor: 6.150

8.  New VMD2 gene mutations identified in patients affected by Best vitelliform macular dystrophy.

Authors:  D Marchant; K Yu; K Bigot; O Roche; A Germain; D Bonneau; V Drouin-Garraud; D F Schorderet; F Munier; D Schmidt; P Le Neindre; C Marsac; M Menasche; J L Dufier; R Fischmeister; C Hartzell; M Abitbol
Journal:  J Med Genet       Date:  2007-02-07       Impact factor: 6.318

9.  A model of best vitelliform macular dystrophy in rats.

Authors:  Alan D Marmorstein; J Brett Stanton; John Yocom; Benjamin Bakall; Marc T Schiavone; Claes Wadelius; Lihua Y Marmorstein; Neal S Peachey
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-10       Impact factor: 4.799

10.  Mouse bestrophin-2 is a bona fide Cl(-) channel: identification of a residue important in anion binding and conduction.

Authors:  Zhiqiang Qu; Rodolphe Fischmeister; Criss Hartzell
Journal:  J Gen Physiol       Date:  2004-04       Impact factor: 4.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.